Research in the construction of comprehensive evaluation systems of drugs in China

doi:10.19803/j.1672-8629.20220171

Abstract

Abstract: Objective To summarize the research progress of clinical evaluation system construction, discuss the clinical evaluation system suitable for Chinese conditions, and provide reference for the development of clinical evaluation of drugs. Methods Domestic and foreign literature on the construction of comprehensive evaluation system was searched and the latest progress of the construction process of comprehensive evaluation system was reviewed. Results Such as the UK and the US, drug evaluation was mainly aimed at the formulation and decision of drug list. The system construction had a certain foundation, and drug selection methods, evaluation indexes and proofreading methods were relatively standardized.In our country, the evaluation based on hospital drugs selection is gradually developed and improved, but the evaluation system is still in the exploratory stage. Conclusion The construction of comprehensive drug evaluation system can include several aspects, such as the construction of professional evaluation subject, standardized evaluation process, appropriate evaluation index system, scientific evaluation method, strict review system.

Key words: drug evaluation, comprehensive drug evaluation, comprehensive evaluation system

CLC Number:

R95
R994.11

YUE Xiaolin, LU Song, ZHANG Lan. Research in the construction of comprehensive evaluation systems of drugs in China[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.

References

[1] ZHAO YL, HAN S, GUAN XD, et al.The enlightenment of American drug effect evaluation Program to Chinese drug evaluation system[J].Chinese Journal of Pharmacy(中国药学杂志), 2015, 50(13): 1156-1159.
[2] National Health Commission. Notice of National Health Commission on Drug Use Monitoring and Clinical Comprehensive Evaluation[EB/OL]. (2014-09-02)[2022-04-19].http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=31149bb1845e4c019a04f30c0d69c2c9.
[3] National Health Commission.Next year, the scope of drug use monitoring will basically cover public medical institutions at level two and above[J]. Modern Health(现代养生), 2019(8): 2.
[4] Members of the Project Team. Reference outline of guidelines for comprehensive evaluation of Chinese drugs[J]. Drug Evaluation(药品评价), 2015, 12(8):26.
[5] CHEN Y, CHI X, HE Y, et al.Mapping of health technology assessment in China: situation analysis and international comparison[J]. Int J Technol Assess Health Care, 2019, 35(5): 401-407.
[6] MCDONAGH MS, JONAS DE, GARTLEHNER G, et al.Methods for the drug effectiveness review project[J]. BMC Medical Research Methodology, 2012, 12(1): 140.
[7] VANLARE JM, WONG HH, GIBBS J, et al.Comparative effectiveness research in practice: the drug effectiveness review project experience[J]. J Comp Eff Res, 2013, 2(6): 541-550.
[8] AHRQ Publication.Methods guide for effectiveness and comparative effectiveness reviews[M]. MD:AHRQ, 2014.
[9] BIRCH S, GAFNI A.On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales[J]. Health Econ, 2002, 11(3): 185-191.
[10] ZHENG YM, WU J.Hate or use? A brief look at the application status of UK health technology assessment[J]. Chinese Pharmacoeconomics(中国药物经济学), 2010, 5(2): 77-86.
[11] HILL SR.Zaheer-Ud-Din babar(ed): pharmaceutical prices in the 21^st century[J]. Pharmacoeconomics, 2015, 34(3): 1-2.
[12] National Institute for Health and Care Excellence. Guide to the Processes of Technology Appraisal[EB/OL]. (2014-09-02)[2022-04-19]. https://pubmed.ncbi.nlm.nih.gov/27905710/.
[13] YUE XF, ZHANG F, LIU YH, et al.Decision-making transformation mechanism and enlightenment of NICE health technology assessment process in UK[J]. Chinese Health Economics(中国卫生经济), 2021, 40(1): 91-96.
[14] BATTISTA RN, FEENY DH, HODGE MJ.Evaluation of the Canadian coordinating office for health technology assessment[J]. Int J Technol Assess Health Care, 1995, 11(1): 102-116.
[15] WU CH.Status of health technology assessment in Canada[J]. Chinese Medicine Biotechnology(中国医药生物技术), 2007, 2(2): 157-158.
[16] Australian Government Department of Health. Therapeutic goods administration australian register of therapeutic goods[EB/OL]. (2019-10-29)[2022-04-19]. https://www.tga.gov.au/australian-register-therapeutic-goods.
[17] Australian Government Department of Health. TGA and PBAC parallel process and requirements[EB/OL]. (2021-09-22)[2022-04-19]. https://www.pbs.gov.au/info/publication/factsheets/shared/tga-pbac-parallel-process.
[18] ZHU Y, JIANG R, SHAO R.Research on parallel procedures of drug registration and medical insurance access in Australia[J]. China Health Economy, 2018, 37(11): 89-92.
[19] LIU GN, HU SL, WU JH. China pharmacoeconomic evaluation guide (2011 Edition)[J]. Chinese Pharmacoeconomics(中国药物经济学), 2011(3): 6-9, 11-48.
[20] SUN X, TAN J, TANG L, et al.A technical framework system for post-marketing drug evaluation based on real-world evidence: reflections and suggestions[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2018, 18(4): 277-283.
[21] ZHANG ZZ, CHEN C, LIU X, et al.Investigation on the application status of health technology assessment in my country[J]. Medical Information(医学信息), 2019, 32(23): 22-25.
[22] TANG JB.Significance and method of clinical drug evaluation[J]. Chinese Pharmacy(中国药房), 1996, 7(6): 243-246.
[23] HUANG SP.Significance and methods of clinical drug evaluation[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2000, 6(1): 8-9.
[24] SHANG PH, LIU J, LIU JT, et al.Research on the comprehensive evaluation index system of drug safety in China[J]. China Health Policy Research(中国卫生政策研究), 2013, 6(10): 41-47.
[25] WEI FF, FENG XC, ZHONG L, et al.Construction of drug safety index based on multi-index comprehensive evaluation method[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(9): 545-550.
[26] GUO Q.New metrics for drug evaluation[J]. China Pharmaceutical Affairs(中国药事), 1997, 11(5): 72.
[27] China Pharmacoeconomic Evaluation Guidelines research group. China pharmacoeconomic evaluation guidelines (2011 edition)[J]. China Journal of Pharmaceutical Economics(中国药物经济学), 2011 (3):7-48.
[28] GAO HL, LU Y, JIANG TT, et al.Guidelines for quality assessment of pharmacoeconomic evaluation reports[J]. Chinese Pharmacoeconomics(中国药物经济学), 2019, 14(2): 18-28.
[29] LIU BL.Consideration of key technical points in clinical trials of new traditional Chinese medicines for the treatment of stroke[J]. Chinese Journal of New Drugs(中国新药杂志), 2015, 24(10): 1105-1107, 1127.
[30] LIU BL.Efficacy evaluation indicators and common evaluation methods in drug clinical trials[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(18):2074-2077.
[31] LIU BL.Selection of curative effect indicators in drug clinical trials[J]. Chinese Journal of New Drugs(中国新药杂志), 2017, 26(18): 2113-2120.
[32] ZHANG HH, WNAG JF, FAN H,et al.Comprehensive evaluation of daptomycin based on Reference Outline of the Guidelines for Comprehensive Evaluation of Drugs in China-Evaluation of Pharmacological Properties in Vivo[J]. Drug Evaluation(药品评价), 2016, 13(8): 8-12, 59.
[33] WANG JF, FAN H, MA K.Evaluation of the effectiveness of daptomycin based on Reference Outline of the Guidelines for Comprehensive Evaluation of Drugs in China[J].Drug Evaluation(药品评价), 2016, 13(6): 19-23,36.
[34] WANG JF, FAN H, MA K.Comprehensive evaluation of daptomycin--safety evaluation based on reference outline of the guidelines for comprehensive evaluation of drugs in China[J]. Drug Evaluation(药品评价), 2015, 12(18): 12-18,32.
[35] XU XW, LIU RJ, MEI D, et al.Comprehensive evaluation of rebif(recombinant interferon β1a) according to reference outline of the guidelines for comprehensive evaluation of drugs in China[J]. Chinese Journal of Pharmacy(中国药学杂志), 2015, 50(12): 1070-1074.
[36] ZHAO ZG, DONG ZJ, LIU JP.Quick guide for drug evaluation and selection in Chinese medical institutions[J]. Medicine Herald(医药导报), 2020, 39(11): 1457-1465.
[37] KONG FX, MA AX, LI HC, et al.Definition, measurement and evaluation of comprehensive clinical value of drugs in the perspective of public decision-making[J]. Chinese Pharmacy(中国药房), 2020, 31(5): 539-544.
[38] Department of Drug Policy and Essential Drug System, National Health Commission. Announcement on Public Solicitation of Opinions on Management Guidelines for Comprehensive Clinical Evaluation of Drugs[EB/OL]. (2020-11-04)[2022-04-19]. http://www.nhc.gov.cn/yaozs/s7656/202011/d11ddc32fae84121a0dfca36b015a31d.shtml.
[39] XIAO Y, NI X, ZHAO K, et al.Research on method guidefor pediatric drug evaluation[J].Chinese Journal of Drug Evaluation(中国药物评价), 2021, 38(6): 479-483.
[40] The National Center for Comprehensive Evaluation of Drug and Health Technology. Technical Guidelines for Comprehensive Clinical Evaluation of Antitumor Drugs (2021 Edition)[EB/OL]. (2021-12-31)[2022-01-19].http:/www.nhei.cn/nhei/znfb/202112/9e350a54d2ea4c3ab9a0237ee4eab9f0.shtml.
[41] The Health Development Research Center of the National Health Commission.Technical guidelines for clinical comprehensive evaluation of cardiovascular disease drugs:2021 edition[EB/OL].(2021-12-31)[2022-03-22].http://www.nhei.cn/nhei/znfb/202112/9e350-a54d2ea4c3ab9a0237ee4eab9f0/files/0ac56e4cd1e848da-859d623212dd0171.pdf.
[42] LIU F, ZHAI SD.Reference outline of guidelines for comprehensive evaluation of drugs in China (second edition) chapter C guidelines for evaluation of drug effectiveness[J]. Drug Evaluation(药品评价), 2015, 12(8): 8-11.
[43] WU JH.Reference outline of guidelines for comprehensive evaluation of drugs in china (second edition) chapter vi guidelines for economic evaluation of clinical drugs[J]. Drug Evaluation(药品评价), 2015, 12(8): 16-19.
[44] SUN CH.Reference Outline of Guidelines for Comprehensive Evaluation of Drugs in China (Second Edition) ChapterⅤ Guidelines for Evaluation of Drug Compliance[J]. Drug Evaluation(药品评价), 2015, 12(8): 15-16.
[45] ZHANG YF, WANG SW, FAN GR.Comprehensive clinical evaluation of nivolumab and pembrolizumab[J]. South-Central Pharmacy(中南药学), 2019, 17(8): 1274-1279.
[46] DENG T, WANG Y, HUANG D, et al.Clinical practice guideline development method-GRADE method theory[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine(中国循证心血管医学杂志), 2018, 10(12): 1441-1445, 1449.
[47] SHI NN.Research on the formulation procedure of TCM clinical practice guidelines based on comprehensive methods[D]. Beijing: China Academy of Chinese Medical Sciences, 2016.
[48] HE W.Concept analysis and type introduction of post-marketing evaluation of drugs in China[J]. South-Central Pharmacy(中南药学), 2015, 13(7): 780-782.
[49] BAN YQ, XIA XD, YUAN XL, et al.A brief analysis of the research status of post-marketing drug evaluation in China[C]. Proceedings of the 2013 Annual Meeting of the Pharmacy Management Professional Committee of the Chinese Pharmaceutical Association and the Academic Forum on “Medical Safety and Scientific Development”(Volume 2), 2013: 143-147.
[50] SHAN SS, WANG QW, WEN JG.Basic concepts and development norms of clinical guidelines and expert consensus[J]. Chinese Journal of Pediatric Surgery(中华小儿外科杂志), 2020, 41(2): 107-111.
[51] CHEN M, QIN K, SHEN J, et al.Application of delphi method to evaluate the index system of nutritional support pharmaceutical care mode[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(22): 2366-2371.
[52] YANG P, LU S, DONG XZ, et al.Research progress on comprehensive evaluation methods of drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 803-806.
[53] JANKNEGT R, VAN DER KUY A, DECLERCK G, et al. Drug selection by means of the system of objectified judgement analysis (SOJA) method[J]. Pharmacoeconomics, 1996, 10(2): 152-63.
[54] JANKNEGT R.Triptans in the treatment of migraine: drug selection by means of the SOJA method[J]. Expert Opin Pharmacother, 2007, 8(Suppl1): S15-30.
[55] XIE TT, GUO DH.Drug evaluation research and progress[J]. Drug Application and Monitoring in China(中国药物应用与监测), 2019, 16(4): 191-195.
[56] WEI XD.“Interventions”in pilot studies[J]. Journal of Clinical Pediatric Surgery(临床小儿外科杂志), 2019, 18(7): 547.
[57] DHILLON JK, GILL NC.Deciphering the system of a systematic review[J]. Dent Res J (Isfahan), 2014, 11(5): 531-536.
[58] HARRIS JD, QUATMAN CE, MANRING MM, et al.How to write a systematic review[J]. Am J Sports Med, 2014, 42(11): 2761-2768.
[59] TIAN L, GUAN X, MA AX.Systematic comparison of randomized controlled trial studies and observational studies[J]. Chinese Pharmacy(中国药房), 2018, 29(4): 493-496.
[60] ZHANG XB, GUAN HJ, LIU GE.Pharmacoeconomic evaluation of recombinant human interferon uman interferon recombinant human interferon apillomavirus infection[J]. Chinese Pharmacoeconomics(中国药物经济学), 2019, 14(10): 28-37.
[61] JIN YH, WU SW, BAI ZG, et al.The connotation and value of systematic evaluation and meta-analysis[J]. Journal of Tongji University (Medical Edition)(同济大学学报医学版), 2019, 40(1): 105-111.
[62] DELGADO-RODRIGUEZ M, SILLERO-ARENAS M.Systematic review and meta-analysis[J]. Med Intensiva (Engl Ed), 2018, 42(7): 444-453.
[63] SUN X, TAN J, TANG L, et al.Real world evidence: experience and lessons from China[J]. BMJ, 2018, 360(feb059): j5262.
[64] BOULKEDID R, ABDOUL H, LOUSTAU M, et al.Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review[J]. PLoS One, 2011, 6(6): e20476.
[65] ZHANG LJ, ZHANG XQ.Peer review quality control mechanism and enlightenment of foreign scientific research funding institutions[J]. Technological Progress and Countermeasures(科技进步与对策), 2017, 34(11): 114-117.
[66] GUO ZJ, YANG AH.The Development characteristics and experience enlightenment of national science foundation[J]. Research on Dialectics of Nature(自然辩证法研究), 2019, 35(12): 63-68.
[67] XU XW.Reference outline of guidelines for comprehensive evaluation of drugs in China-chapter Ⅰ guidelines for drug safety evaluation[J]. Drug Evaluation(药品评价), 2015, 12(8): 7.